JP2007523856A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007523856A5 JP2007523856A5 JP2006517316A JP2006517316A JP2007523856A5 JP 2007523856 A5 JP2007523856 A5 JP 2007523856A5 JP 2006517316 A JP2006517316 A JP 2006517316A JP 2006517316 A JP2006517316 A JP 2006517316A JP 2007523856 A5 JP2007523856 A5 JP 2007523856A5
- Authority
- JP
- Japan
- Prior art keywords
- testosterone
- serum
- day
- concentration
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 47
- 229960003604 Testosterone Drugs 0.000 description 19
- 210000002966 Serum Anatomy 0.000 description 12
- 230000000275 pharmacokinetic Effects 0.000 description 5
- 210000004369 Blood Anatomy 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 208000001640 Fibromyalgia Diseases 0.000 description 3
- 229940088597 Hormone Drugs 0.000 description 3
- 230000037165 Serum Concentration Effects 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000035533 AUC Effects 0.000 description 2
- 230000037242 Cmax Effects 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 240000008526 Hypericum perforatum Species 0.000 description 2
- 235000017309 Hypericum perforatum Nutrition 0.000 description 2
- 235000002197 St. John’s wort Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229940102465 ginger root Drugs 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 239000001841 zingiber officinale Substances 0.000 description 2
- 229940030486 ANDROGENS Drugs 0.000 description 1
- 206010000496 Acne Diseases 0.000 description 1
- 108010082126 Alanine Transaminase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 230000036888 Average AUC Effects 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 229940107161 Cholesterol Drugs 0.000 description 1
- 229960003624 Creatine Drugs 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 102100010966 GPT Human genes 0.000 description 1
- 108060003412 GRP Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000000509 Infertility Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 230000036917 MEAN CMAX Effects 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000006641 Skin Disease Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000035569 catabolism Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine zwitterion Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 235000020828 fasting Nutrition 0.000 description 1
- 230000002489 hematologic Effects 0.000 description 1
- 230000003054 hormonal Effects 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000002117 illicit drug Substances 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 230000002085 persistent Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Description
小児、妊婦、およびホルモン治療、ホルモン避妊薬、または不妊薬を受けている女性は除外した。診断未確定の膣からの出血が報告された場合、体格指数BMIが30より大きい場合、エタノールまたは違法医薬品濫用が認められた場合、活動性の血栓性静脈炎、乳癌、高血圧(薬物治療の有無を問わず、5分着席後に収縮期/拡張期血圧が160/95を超えるもの)、または重大な皮膚疾患、座瘡もしくは多毛症を有する場合、女性を研究から除外した。登録に先立って、被験患者の血液について以下の一般健康基準に関する検査を行った(カッコ内は除外基準):脂質プロファイルによる心臓リスク要因---空腹時総コレステロール(>240mg/dL)、高密度リポタンパク質(<35mg/dL)、低密度リポタンパク質(>210mg/dL)、トリグリセリド(>300mg/dL);アラニンアミノトランスフェラーゼ(>1.5×N(正常値)、正常値は0〜40U/L)、アルカリホスファターゼ(>2×N、正常値は40〜120U/L)、アスパラギン酸アミノトランスフェラーゼ(>1.5×N、正常値は10〜30U/L)、血清アルブミン(>N、正常値は3.2〜5.2g/dL)、総ビリルビン(>N、正常値は0.2〜1.3mg/dL)、および直接(抱合型、可溶性)ビリルビン(>N、正常値は0.0〜0.3mg/dL)による肝機能;血中尿素窒素(>2×N、正常値は8〜18U/dL)および血清クレアチン検査(>N、正常値は0.7〜1.2mg/dL)による腎機能;血液学的機能は、ヘモグロビン(正常値、12〜16g/dL)についての検査を含む完全血球計算により評価した。テストステロン治療が、被験患者の一般的な健康に不都合に作用したかを評価するために、研究の最後に血液検査および身体検査を行った。血清総テストステロン(>0.4ng/mL)およびFSH(<22IU/L)を、基準範囲(reference range)の下半分(lower half)のテストステロン濃度を患者が有することを確認し(18人中2人の患者がテストステロン濃度に基づき除外された)、閉経後状態を決定するために検査した(一晩絶食後の午前8時)。<22IU/LのFSH濃度は、閉経前または閉経周辺期状態であること、したがって、両方の卵巣摘出術を受けていない限り、適切な避妊が必要であることを示す。テストステロン血清濃度は、循環アンドロゲンの小幅な24時間周期リズムのために午前8時に検査した。最も頻繁に適用される除外基準は、BMI>30であった。セイヨウオトギリソウは、肝臓で、解毒作用のある酵素複合体、CYP3Aの活性化によりホルモンの異化作用を誘発することが知られているため、患者はセイヨウオトギリソウの服用の中止を求められた。上記の適格基準に適合する12人の患者について、圧痛点評価、線維筋痛症診断の確認および一般健康評価を含む身体検査の予定を組んだ。
血中テストステロン濃度データの分析は、血清総テストステロン濃度が、線維筋痛症患者へのテストステロンゲルによるホルモン補充療法に応答して、確実に上昇することを明らかにした。1日目および28日目の経時的な血清フリーテストステロン濃度のデータを図1に示す。血清テストステロンデータの、女性の血清総テストステロン濃度の標準基準範囲との比較により、本研究の線維筋痛症患者は、当初、基準範囲の下半分の総テストステロン濃度であったことが確認された。しかし、1日目におけるホルモンの最初の用量の適用の24時間後、血清総テストステロン濃度の平均は、1日目の0時の血清濃度平均より有意に高く(図1、p=0.01)、これは、血清濃度が、28日間のタイムコース中、概して早い段階で、持続性となったことを示すものである。定常状態濃度には、24時間サンプリングの初めと終わりの平均濃度が同様であったことにより証明されるように、28日までに到達した(図1参照)。個人間をベースに分析した場合、血清テストステロンの24時間プロファイルには違いがあり、これは、このホルモンについて知られている複雑な調節に一致する。薬学動態パラメータ分析の概要は、テストステロン治療に応答して、総テストステロン最大濃度の平均が有意に増加することを明らかにした:Cmaxは、1日目の1.21ng/mLと比較して28日目で1.92ng/mLであり、p<0.05であった。総テストステロンの濃度曲線下面積の平均(24時間プロファイリング期間にわたって評価)の有意な増加もまた見いだされた:AUCは、1日目の18.36ng−h/mLと比較し、28日目で28.75ng−h/mLであり、p<0.05であった。総合して薬学動態データを考慮すると、治療により、血清総テストステロン濃度は、初期に、初めの3時間で素早く上昇し、その後、経時的に確実に持続することが明らかにされた。加えて、血清テストステロン濃度平均は、閉経前女性の基準範囲の下限から、ちょうど基準範囲の上限に上昇した。
血清中の遊離テストステロンの濃度も検査し、薬学動態分析に供した。総テストステロンの結果に類似する結果が得られた。しかし、12人の患者のうち2人が、治療前から治療の間中、異常に高い遊離テストステロン濃度を有した。残りの患者の個々のプロファイルは、閉経後の範囲から、閉経前の基準範囲および閉経後基準範囲の上部へと増加した濃度を示した。薬学動態パラメータ分析の概要は、遊離テストステロンのCmaxの平均が、1日目で3.68pg/mLであるのに対し、28日目は4.69pg/mLであり(p>0.05)、遊離テストステロンのAUCの平均が、1日目で54.35pg−h/mLであるのに対し、28日目で71.38pg−h/mLであることを示した。遊離テストステロンのCmaxおよびAUCは、28日目の値から1日目のベースラインを引き算することで証明されるように、治療により増加したが、例外的に高い遊離テストステロン濃度を有する2つの個体のために、統計的な有意性は、これらの薬学動態パラメータでは達成されなかった。これら2人の患者の遊離テストステロン濃度の高さは、これら特定の個人の総テストステロンプロファイルが正常であるのと対照的であり、これは、他の説明が存在するものの、これらの高い遊離ホルモン濃度が、血清中のグロブリンに結合した性ホルモン濃度が低いことによりもたらされた可能性を高めるものである。これら研究対象の両方により報告されたが、他のいずれの対象も使用していなかった薬剤またはサプリメントは、しょうが根のみであった(しょうが根が、遊離テストステロンの酵素結合免疫測定、または性ホルモン結合グロブリンの代謝もしくは結合パラメータに干渉することは知られていない)。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/464,310 | 2003-06-18 | ||
US10/464,310 US20040259852A1 (en) | 2003-06-18 | 2003-06-18 | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
PCT/US2004/019201 WO2005000236A2 (en) | 2003-06-18 | 2004-06-15 | Transdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011126449A Division JP5651540B2 (ja) | 2003-06-18 | 2011-06-06 | 線維筋痛症候群または慢性疲労症候群の処置のための経皮的組成物および方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2007523856A JP2007523856A (ja) | 2007-08-23 |
JP2007523856A5 true JP2007523856A5 (ja) | 2011-08-25 |
JP5717312B2 JP5717312B2 (ja) | 2015-05-13 |
Family
ID=33517268
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006517316A Expired - Fee Related JP5717312B2 (ja) | 2003-06-18 | 2004-06-15 | 線維筋痛症候群または慢性疲労症候群の処置のための経皮的組成物および方法 |
JP2011126449A Expired - Fee Related JP5651540B2 (ja) | 2003-06-18 | 2011-06-06 | 線維筋痛症候群または慢性疲労症候群の処置のための経皮的組成物および方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011126449A Expired - Fee Related JP5651540B2 (ja) | 2003-06-18 | 2011-06-06 | 線維筋痛症候群または慢性疲労症候群の処置のための経皮的組成物および方法 |
Country Status (6)
Country | Link |
---|---|
US (3) | US20040259852A1 (ja) |
EP (2) | EP2000143B1 (ja) |
JP (2) | JP5717312B2 (ja) |
AU (2) | AU2004251075B2 (ja) |
CA (1) | CA2529575C (ja) |
WO (1) | WO2005000236A2 (ja) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69737883T2 (de) | 1996-04-25 | 2008-03-06 | Bioarray Solutions Ltd. | Licht-regulierte, elektrokinetische zusammensetzung von partikeln an oberflächen |
US9709559B2 (en) | 2000-06-21 | 2017-07-18 | Bioarray Solutions, Ltd. | Multianalyte molecular analysis using application-specific random particle arrays |
US7262063B2 (en) | 2001-06-21 | 2007-08-28 | Bio Array Solutions, Ltd. | Directed assembly of functional heterostructures |
EP1463825B1 (en) | 2001-10-15 | 2017-12-06 | BioArray Solutions Ltd. | Multiplexed analysis of polymorphic loci by concurrent interrogation and enzyme-mediated detection |
AU2003298655A1 (en) | 2002-11-15 | 2004-06-15 | Bioarray Solutions, Ltd. | Analysis, secure access to, and transmission of array images |
US20040259852A1 (en) * | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
US8883769B2 (en) * | 2003-06-18 | 2014-11-11 | White Mountain Pharma, Inc. | Methods for the treatment of fibromyalgia and chronic fatigue syndrome |
US9511079B2 (en) | 2003-06-18 | 2016-12-06 | White Mountain Pharma, Inc. | Methods for the treatment of fibromyalgia and chronic fatigue syndrome |
WO2005031305A2 (en) | 2003-09-22 | 2005-04-07 | Bioarray Solutions, Ltd. | Surface immobilized polyelectrolyte with multiple functional groups capable of covalently bonding to biomolecules |
CA2899287A1 (en) | 2003-10-28 | 2005-05-12 | Bioarray Solutions Ltd. | Optimization of gene expression analysis using immobilized capture probes |
PT1530965E (pt) | 2003-11-11 | 2006-05-31 | Udo Mattern | Sistema de administracao de libertacao controlada de hormonas sexuais para aplicacao nasal |
US8784869B2 (en) | 2003-11-11 | 2014-07-22 | Mattern Pharma Ag | Controlled release delivery system for nasal applications and methods of treatment |
KR101292492B1 (ko) | 2004-05-11 | 2013-08-01 | 이모셔널 브레인 비.브이. | 약제학적 제형물 및 여성 성기능 부전의 치료에서 그것의용도 |
US7848889B2 (en) | 2004-08-02 | 2010-12-07 | Bioarray Solutions, Ltd. | Automated analysis of multiplexed probe-target interaction patterns: pattern matching and allele identification |
EP1790343A1 (en) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
PT2068825E (pt) | 2006-10-04 | 2011-02-11 | M & P Patent Ag | Sistema de administração de libertação controlada para aplicação nasal de neurotransmissores |
EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
CA2643529C (en) * | 2008-11-06 | 2019-05-21 | Kenneth W. Adams | Method and composition for enhancement of male erectile function |
EP2640398A4 (en) * | 2010-11-18 | 2014-05-14 | White Mountain Pharma Inc | METHODS FOR TREATING CHRONIC OR REFRACTORY PAIN AND / OR INCREASING PAIN THRESHOLD IN A SUBJECT, AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS |
US20130040923A1 (en) | 2011-05-13 | 2013-02-14 | Trimel Pharmaceuticals Corporation | Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
US20130045958A1 (en) | 2011-05-13 | 2013-02-21 | Trimel Pharmaceuticals Corporation | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
HRP20211377T1 (hr) | 2011-11-23 | 2022-01-07 | Therapeuticsmd, Inc. | Prirodne kombinirane hormonske supstitucijske formulacije i terapije |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11744838B2 (en) | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
CA2947767A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
CA2951284A1 (en) | 2014-07-29 | 2016-02-04 | Therapeuticsmd, Inc. | Transdermal cream |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
JP2019513709A (ja) | 2016-04-01 | 2019-05-30 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | ステロイドホルモン薬学的組成物 |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US11904006B2 (en) | 2019-12-11 | 2024-02-20 | University Of Iowa Research Foundation | Poly(diaminosulfide) particle-based vaccine |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
WO2022271951A1 (en) | 2021-06-23 | 2022-12-29 | University Of Iowa Research Foundation | Sustained release formulations comprising a selective androgen receptor modulator |
WO2024026224A1 (en) * | 2022-07-29 | 2024-02-01 | University Of Rochester | Methods for improving muscle mass, strength, or function with a combination of testosterone and growth hormone |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4542129A (en) * | 1982-08-16 | 1985-09-17 | Norman Orentreich | DHEA Formulations and methods for treating dry skin |
US5019395A (en) * | 1988-03-08 | 1991-05-28 | Warner-Lambert Company | Compositions with enhanced penetration |
US5461042A (en) * | 1988-12-30 | 1995-10-24 | Loria; Roger M. | Regulation of the immune system |
US5206008A (en) * | 1991-04-15 | 1993-04-27 | Virginia Commonwealth University | Enhancement of immune response |
US5676968A (en) * | 1991-10-31 | 1997-10-14 | Schering Aktiengesellschaft | Transdermal therapeutic systems with crystallization inhibitors |
US5656606A (en) * | 1995-02-17 | 1997-08-12 | Merck & Co., Inc. | Camphor compounds promote release of growth hormone |
US6923983B2 (en) * | 1996-02-19 | 2005-08-02 | Acrux Dds Pty Ltd | Transdermal delivery of hormones |
AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
DE19619045C1 (de) * | 1996-05-02 | 1997-11-13 | Jenapharm Gmbh | Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen |
US5709878A (en) * | 1996-08-02 | 1998-01-20 | Rosenbaum; Jerry | Transdermal delivery of dehydroepiandrosterone |
US5855920A (en) * | 1996-12-13 | 1999-01-05 | Chein; Edmund Y. M. | Total hormone replacement therapy |
DE19701949A1 (de) * | 1997-01-13 | 1998-07-16 | Jenapharm Gmbh | Transdermales therapeutisches System |
AU6265998A (en) * | 1997-02-07 | 1998-08-26 | Theratech, Inc. | Composition and method for supplementing testosterone in women with symptoms of testosterone deficiency |
US6015786A (en) * | 1997-02-25 | 2000-01-18 | Celtrix Pharmaceuticals, Inc. | Method for increasing sex steroid levels using IGF or IGF/IGFBP-3 |
SK116199A3 (en) * | 1997-02-28 | 2000-01-18 | Minnesota Mining & Mfg | Transdermal device for the delivery of testosterone |
US5968919A (en) * | 1997-10-16 | 1999-10-19 | Macrochem Corporation | Hormone replacement therapy drug formulations for topical application to the skin |
US20020013304A1 (en) * | 1997-10-28 | 2002-01-31 | Wilson Leland F. | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
US6319913B1 (en) * | 1997-11-10 | 2001-11-20 | Cellegy Pharmaceuticals, Inc. | Penetration enhancing and irritation reducing systems |
US5869090A (en) * | 1998-01-20 | 1999-02-09 | Rosenbaum; Jerry | Transdermal delivery of dehydroepiandrosterone |
US5935949A (en) * | 1998-03-20 | 1999-08-10 | Trustees Of Dartmouth College | Use of androgen therapy in fibromyalgia and chronic fatigue syndrome |
US6165504A (en) | 1998-09-23 | 2000-12-26 | Barr Laboratories, Inc. | Methods for treating hot flashes and improving the quality of life of castrated prostatic cancer patients |
FR2801507B1 (fr) | 1999-11-30 | 2003-06-27 | Pf Medicament | Dispositif transdermique auto-adhesif comprenant un reservoir et une matrice contenant le meme principe actif, son procede de preparation et ses utilisations |
EP1280777B1 (en) * | 2000-05-11 | 2005-11-23 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
US7198801B2 (en) * | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
US20040198706A1 (en) * | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
ATE355854T1 (de) * | 2000-08-03 | 2007-03-15 | Antares Pharma Ipl Ag | Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel |
US20030139384A1 (en) * | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
IL154693A0 (en) * | 2000-08-30 | 2003-09-17 | Unimed Pharmaceuticals Inc | Method of increasing testosterone and related steroid concentrations in women |
US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
WO2002017927A1 (en) * | 2000-08-30 | 2002-03-07 | Unimed Pharmaceuticals, Inc. | Method for treating erectile dysfunction and increasing libido in men |
US20040002482A1 (en) | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
US6573258B2 (en) * | 2000-09-27 | 2003-06-03 | Frontier Scientific, Inc. | Photodynamic porphyrin antimicrobial agents |
WO2002055020A2 (en) * | 2000-12-11 | 2002-07-18 | Testocreme Llc | Topical testosterone formulations and associated methods |
US20030027833A1 (en) | 2001-05-07 | 2003-02-06 | Cleary Gary W. | Compositions and delivery systems for administration of a local anesthetic agent |
US20030027804A1 (en) * | 2001-06-27 | 2003-02-06 | Van Der Hoop Roland Gerritsen | Therapeutic combinations for the treatment of hormone deficiencies |
WO2003028667A2 (en) * | 2001-10-04 | 2003-04-10 | Cellegy Pharmaceuticals, Inc. | Semisolid topical hormonal compositions and methods for treatment |
US7169107B2 (en) * | 2002-01-25 | 2007-01-30 | Karen Jersey-Willuhn | Conductivity reconstruction based on inverse finite element measurements in a tissue monitoring system |
US7049313B2 (en) * | 2002-02-25 | 2006-05-23 | Kudos Pharmaceuticals Ltd. | ATM inhibitors |
OA12856A (en) | 2002-03-15 | 2006-09-15 | Unimed Pharmaceuticals Inc | Androgen pharmaceutical composition and method for treating depression. |
AU2003228314C1 (en) | 2002-03-15 | 2009-03-26 | Besins Healthcare Luxembourg Sarl | Androgen pharmaceutical composition and method for treating depression |
MY139721A (en) * | 2002-04-19 | 2009-10-30 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
US8883769B2 (en) | 2003-06-18 | 2014-11-11 | White Mountain Pharma, Inc. | Methods for the treatment of fibromyalgia and chronic fatigue syndrome |
US20040259852A1 (en) * | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
US20040259784A1 (en) * | 2003-06-18 | 2004-12-23 | White Hillary D. | Compositions and methods for treatment of muscle pain and muscle wasting |
US20050042268A1 (en) * | 2003-07-16 | 2005-02-24 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
US20050020552A1 (en) * | 2003-07-16 | 2005-01-27 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
US20050025833A1 (en) * | 2003-07-16 | 2005-02-03 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
BRPI0414551B8 (pt) | 2003-10-10 | 2021-05-25 | Antares Pharma Ipl Ag | formulação farmacêutica transdérmica ou transmucosa e método de protelação ou inibição da cristalização de um agente ativo |
EP2374508A1 (en) | 2005-03-21 | 2011-10-12 | Vicus Therapeutics SPE 1, LLC | Combination of angiotension receptor blockers (ARB) and NSAIDs for use in ameliorating cachexia |
CA2604400A1 (en) | 2005-04-12 | 2006-10-19 | Unimed Pharmaceuticals, Inc. | Method of treating or preventing bone deterioration or osteoporosis |
KR20080016552A (ko) * | 2005-04-13 | 2008-02-21 | 유니메드 파마슈티칼스, 인크. | 여성의 테스토스테론 및 관련된 스테로이드의 농도를증가시키는 방법 |
DK2985026T3 (da) | 2005-04-15 | 2022-10-31 | Clarus Therapeutics Inc | Farmaceutiske leveringssystemer til hydrofobe lægemidler og sammensætninger dermed |
US8492369B2 (en) | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
NZ563946A (en) | 2005-06-03 | 2012-02-24 | Acrux Dds Pty Ltd | Testosterone containing non-occlusive transdermal drug delivery composition for application to the arm pit / axilla |
US20080261937A1 (en) | 2007-03-23 | 2008-10-23 | Dudley Robert E | Pharmaceutical compositions and method for treating pediatric hypogonadism |
EP2640398A4 (en) | 2010-11-18 | 2014-05-14 | White Mountain Pharma Inc | METHODS FOR TREATING CHRONIC OR REFRACTORY PAIN AND / OR INCREASING PAIN THRESHOLD IN A SUBJECT, AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS |
-
2003
- 2003-06-18 US US10/464,310 patent/US20040259852A1/en not_active Abandoned
-
2004
- 2004-06-15 AU AU2004251075A patent/AU2004251075B2/en not_active Ceased
- 2004-06-15 JP JP2006517316A patent/JP5717312B2/ja not_active Expired - Fee Related
- 2004-06-15 EP EP08154166.6A patent/EP2000143B1/en not_active Expired - Lifetime
- 2004-06-15 EP EP04776655A patent/EP1638575A4/en not_active Withdrawn
- 2004-06-15 CA CA2529575A patent/CA2529575C/en not_active Expired - Fee Related
- 2004-06-15 WO PCT/US2004/019201 patent/WO2005000236A2/en active Search and Examination
-
2005
- 2005-12-16 US US11/303,813 patent/US7799769B2/en not_active Expired - Fee Related
-
2010
- 2010-07-15 US US12/837,310 patent/US8999963B2/en not_active Expired - Fee Related
-
2011
- 2011-03-02 AU AU2011200914A patent/AU2011200914B2/en not_active Ceased
- 2011-06-06 JP JP2011126449A patent/JP5651540B2/ja not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007523856A5 (ja) | ||
Trenkwalder et al. | L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial | |
Ortola et al. | Elevated plasma atrial natriuretic peptide levels in diabetic rats. Potential mediator of hyperfiltration. | |
Miettinen et al. | Retinopathy predicts coronary heart disease events in NIDDM patients | |
Palomba et al. | Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome | |
Sivitz et al. | Obesity impairs vascular relaxation in human subjects: hyperglycemia exaggerates adrenergic vasoconstriction: Arterial dysfunction in obesity and diabetes | |
Tufano et al. | Anthropometric, hormonal and biochemical differences in lean and obese women before and after menopause | |
Naessen et al. | Menopausal estrogen therapy counteracts normal aging effects on intima thickness, media thickness and intima/media ratio in carotid and femoral arteries: an investigation using noninvasive high-frequency ultrasound | |
Suzuki et al. | Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy | |
Hagiwara et al. | Delayed onset of pulmonary hypertension associated with an appetite suppressant, mazindol-A case report | |
Martinez-Riquelme et al. | Insulin revisited | |
Grabska et al. | Pulse pressure–independent predictor of poor early outcome and mortality following ischemic stroke | |
Harvey et al. | Dose response effect of cyclical medroxyprogesterone on blood pressure in postmenopausal women | |
Wang et al. | OS 12-04 Taurine supplementation lowers blood pressure and reduces carotid intima-media thickness in prehypertension | |
Somani | Aging women and their endothelium: Assessing function and the acute effects of dietary nitrate supplementation | |
Palmer et al. | Migraine revolution and sumatriptan | |
Strojek et al. | Reduced insulin-mediated glucose uptake by euglycemic clamp in offspring of patients with type 2 diabetes | |
Tantisattamo et al. | A14968 New Diagnostic Criteria for Hypertension and Renal Allograft Function | |
Cheng et al. | Comparison of captopril and enalapril in the treatment of hypertension in patients with non-insulin dependent diabetes mellitus and nephropathy | |
Rosenthal et al. | B006: Device-guided breathing exercises reduce blood pressure--ambulatory and home measurements | |
Frisk‐Holmberg | The Effectiveness of Clonidine as an Antihypertensive in a Two‐Dose Regimen | |
Mykytyuk et al. | A11737 Clinical and biochemical peculiarities of Arterial Hypertension in patients with alimentary obesity | |
Bruthans et al. | A11742 Continous improvement of treatable cardiovascular risk factors control in secondary prevention of established coronary heart disease. | |
Trukhanova et al. | A11708 The effects of duration of hemodialysis on the parameters of hemodynamics in patients with end-stage renal disease | |
Fu et al. | PS-P15-6: PERIPHERAL OSTEOPONTIN MIGHT BE A POTENTIAL BIO-MARKER FOR PREDICTING ARTERIAL STIFFNESS IN ELDERLY CHINESE |